{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:38:25Z","timestamp":1792676305474,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Complement is not a niche test area. An expanding group of rare diseases, including hereditary angioedema, atypical hemolytic uremic syndrome, C3 glomerulopathy, and paroxysmal nocturnal hemoglobinuria, now has approved targeted therapies, and the laboratory is central to both diagnosis and treatment monitoring. Yet complement testing remains poorly standardized across institutions, and its preanalytical fragility makes it uniquely susceptible to errors that other immune assays tolerate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>This review offers a working framework for complement diagnostics in the clinical laboratory. We describe the 3 activation pathways and their key regulators and then outline a tiered diagnostic panel: functional assays of classical pathway activity (CH50), alternative pathway activity, protein quantitation (C3, C4, C1q, complement factor H, complement factor I, and C1 inhibitor antigen and function), and activation products (C3d, C4d, Bb, and sC5b-9), and disease-specific autoantibodies. Diagnostic algorithms are presented for the main complement-mediated conditions, with emphasis on the serological features that distinguish 1 disease from another. Preanalytical requirements receive dedicated attention as tube selection, centrifugation temperature, processing delay, and freeze conditions all materially affect results. A practical approach to laboratory-developed test validation is outlined, and we address the interpretive challenges introduced by approved complement inhibitors (eculizumab, ravulizumab, pozelimab, zilucoplan, danicopan, iptacopan, pegcetacoplan, and sutimlimab), whose effects on routine complement assays are not always straightforward. Future directions, including multiplex platforms and artificial intelligence\u2013assisted interpretation, are briefly considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A well-structured complement laboratory, based on rigorous preanalytical practices and validated assays, provides diagnostic information not available from other tests. This review could serve as a practical reference for laboratory clinical biochemists building or optimizing complement diagnostics in their setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfag158","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:43:19Z","timestamp":1792672999000},"source":"Crossref","is-referenced-by-count":0,"title":["Laboratory Diagnosis of Complement-Mediated Diseases: A Practical Overview"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7129-9512","authenticated-orcid":false,"given":"Alessandra","family":"Valentini","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Biochemistry, Tor Vergata University Hospital , Rome ,","place":["Italy"]},{"name":"Department of Experimental Medicine, Tor Vergata University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Biochemistry, Tor Vergata University Hospital , Rome ,","place":["Italy"]},{"name":"Department of Experimental Medicine, Tor Vergata University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"2026102208431312600_jfag158-B1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"2026102208431312600_jfag158-B2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I: molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"2026102208431312600_jfag158-B3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: role in immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"2026102208431312600_jfag158-B4","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"2026102208431312600_jfag158-B5","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood-2015-06-640995","article-title":"Complement in hemolytic anemia","volume":"126","author":"Brodsky","year":"2015","journal-title":"Blood"},{"key":"2026102208431312600_jfag158-B6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"2026102208431312600_jfag158-B7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ekir.2023.12.007","article-title":"C3 glomerulopathy: novel treatment paradigms","volume":"9","author":"Tarragon Estebanez","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026102208431312600_jfag158-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2025.113824","article-title":"Challenges for complement functional assays in the clinical laboratory: from test validation to clinical interpretation","volume":"537","author":"Nandakumar","year":"2025","journal-title":"J Immunol Methods"},{"key":"2026102208431312600_jfag158-B9","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.imbio.2016.06.008","article-title":"Complement analysis 2016: clinical indications, laboratory diagnostics and quality control","volume":"221","author":"Prohaszka","year":"2016","journal-title":"Immunobiology"},{"key":"2026102208431312600_jfag158-B10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"2026102208431312600_jfag158-B11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","article-title":"Therapeutic targeting of the complement system: from rare diseases to pandemics","volume":"73","author":"Garred","year":"2021","journal-title":"Pharmacol Rev"},{"key":"2026102208431312600_jfag158-B12","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/ajh.24209","article-title":"Laboratory tests for disorders of complement and complement regulatory proteins","volume":"90","author":"Shih","year":"2015","journal-title":"Am J Hematol"},{"key":"2026102208431312600_jfag158-B13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2026102208431312600_jfag158-B14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1368399","article-title":"External quality assurance program for diagnostic complement laboratories: evaluation of the results of the past seven years","volume":"15","author":"Kirschfink","year":"2024","journal-title":"Front Immunol"},{"key":"2026102208431312600_jfag158-B15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","article-title":"Hereditary angioedema: causes, manifestations and treatment","volume":"80","author":"Longhurst","year":"2019","journal-title":"Br J Hosp Med"},{"key":"2026102208431312600_jfag158-B16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"2026102208431312600_jfag158-B17","doi-asserted-by":"crossref","first-page":"e1408","DOI":"10.1002\/cti2.1408","article-title":"Anti-C1q autoantibodies from systemic lupus erythematosus patients enhance CD40\u2013CD154-mediated inflammation in peripheral blood mononuclear cells in vitro","volume":"11","author":"Rabatscher","year":"2022","journal-title":"Clin Transl Immunology"},{"key":"2026102208431312600_jfag158-B18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1710-1492-9-29","article-title":"Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe","volume":"9","author":"Zanichelli","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2026102208431312600_jfag158-B19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Hemolytic uremic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"2026102208431312600_jfag158-B20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cyto.b.20525","article-title":"Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry","volume":"78","author":"Borowitz","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"2026102208431312600_jfag158-B21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cyto.b.21610","article-title":"ICCS\/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders, part 2: reagent selection and assay optimization for high-sensitivity testing","volume":"94","author":"Sutherland","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"key":"2026102208431312600_jfag158-B22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/CVI.00607-13","article-title":"Blood collection tubes influence serum ficolin-1 and ficolin-2 levels","volume":"21","author":"Brady","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"2026102208431312600_jfag158-B23","first-page":"484","article-title":"Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation","volume":"73","author":"Mollnes","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"2026102208431312600_jfag158-B24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1309\/AJCPXPD7ZQXNTIAL","article-title":"Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers","volume":"143","author":"Yang","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"2026102208431312600_jfag158-B25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052646","article-title":"Heat-inactivation of human serum destroys C1 inhibitor, promotes immune complex formation, and improves human T cell function","volume":"22","author":"Fante","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026102208431312600_jfag158-B26","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/j.molimm.2007.06.150","article-title":"Complement analysis in the 21st century","volume":"44","author":"Mollnes","year":"2007","journal-title":"Mol Immunol"},{"key":"2026102208431312600_jfag158-B27","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22627","article-title":"Quantification of human C1 esterase inhibitor protein using an automated turbidimetric immunoassay","volume":"33","author":"Tange","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"2026102208431312600_jfag158-B28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697313","article-title":"Expanding horizons in complement analysis and quality control","volume":"12","author":"Frazer-Abel","year":"2021","journal-title":"Front Immunol"},{"key":"2026102208431312600_jfag158-B29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"MAbs"},{"key":"2026102208431312600_jfag158-B30","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"key":"2026102208431312600_jfag158-B31","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"Roth","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102208431312600_jfag158-B32","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102208431312600_jfag158-B33","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","article-title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","volume":"10","author":"Lee","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026102208431312600_jfag158-B34","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/advance-article-pdf\/doi\/10.1093\/jalm\/jfag158\/72350872\/jfag158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/advance-article-pdf\/doi\/10.1093\/jalm\/jfag158\/72350872\/jfag158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:43:24Z","timestamp":1792673004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/advance-article\/doi\/10.1093\/jalm\/jfag158\/8978733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfag158","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"article-number":"jfag158"}}